Tanaya Shree
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tanaya Shree has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Ann Brunson
Center for Oncology Hematology Outcomes Research and Training (COHORT) and Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA
1 shared publicationHolden T. Maecker
Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA
1 shared publicationQian Li
Center for Oncology Hematology Outcomes Research and Training (COHORT) and Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA
1 shared publicationRobert W. Haile
Center for Translational Population Sciences, Cedars-Sinai Medical Center, Los Angeles, CA
1 shared publicationRonald Levy
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
1 shared publicationSally L. Glaser
Cancer Prevention Institute of California, Fremont, CA
1 shared publication
Latest Publications
- 25 April 2022
- Published by Wiley in British Journal of Haematology
- Vol. 197 (6) , 659-661
Can B cell‐deficient patients rely on COVID‐19 vaccine‐induced T‐cell immunity?
Anti-CD20 antibody treatments prevent humoral responses to vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines, but the nature of T-cell responses in this setting is less well understood. Riise et al. assess vaccine-induced epitope-specific CD8 T cell responses in patients with lymphoma recently treated with rituximab and find a wide range of responses, with the most recently treated patients frequently failing to respond, while others exhibit responses stronger than healthy controls. They suggest these epitopes among others could be used in a T cell-targeted vaccine, and such strategies are indeed in clinical trials now.
- 25 April 2022
- Published by Wiley in British Journal of Haematology
- Vol. 197 (6) , 659-661
Can B cell‐deficient patients rely on COVID‐19 vaccine‐induced T‐cell immunity?
Anti-CD20 antibody treatments prevent humoral responses to vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines, but the nature of T-cell responses in this setting is less well understood. Riise et al. assess vaccine-induced epitope-specific CD8 T cell responses in patients with lymphoma recently treated with rituximab and find a wide range of responses, with the most recently treated patients frequently failing to respond, while others exhibit responses stronger than healthy controls. They suggest these epitopes among others could be used in a T cell-targeted vaccine, and such strategies are indeed in clinical trials now.
- 21 February 2020
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 38 (15) , 1664-1675
Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma
PURPOSE: Therapeutic advances for diffuse large B-cell lymphoma (DLBCL) have led to an increasing number of survivors. Both DLBCL and its treatments perturb the immune system, yet little is known about immune health during extended survivorship. METHODS: In this retrospective cohort study, we compared 21,690 survivors of DLBCL from the California Cancer Registry (CCR) to survivors of breast, prostate, head and neck, and melanoma cancers. We linked their CCR records to a statewide database documenting hospital, emergency room, and ambulatory surgery visits and investigated the incidence of autoimmune conditions, immune deficiencies, and infections 1-10 years after cancer diagnosis. RESULTS: We found elevated incidence rate ratios (IRRs) for many immune-related conditions in survivors of DLBCL compared with other cancer survivors, including significantly and consistently elevated IRRs for viral and fungal pneumonias (up to 10.8-fold), meningitis (up to 5.3-fold), as well as humoral deficiency (up to 17.6-fold) and autoimmune cytopenias (up to 12-fold). IRRs for most conditions remained high even in the late survivorship period (5-10 years after cancer diagnosis). The elevated risks could not be explained by exposure to chemotherapy, stem-cell transplantation, or rituximab, except for IRRs for humoral deficiency, which were consistently higher after the incorporation of rituximab into DLBCL treatments. CONCLUSION: To our knowledge, this is the largest cohort study with extended follow-up to demonstrate impaired immune health in survivors of DLBCL. The observed persistent, elevated risks for autoimmune diseases, immune deficiencies, and infectious conditions may reflect persistent immune dysregulation caused by lymphoma or treatment and may lead to excess morbidity and mortality during survivorship. Improved understanding of these risks could meaningfully improve long-term care of patients with DLBCL.
- 21 February 2020
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 38 (15) , 1664-1675
Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma
PURPOSE: Therapeutic advances for diffuse large B-cell lymphoma (DLBCL) have led to an increasing number of survivors. Both DLBCL and its treatments perturb the immune system, yet little is known about immune health during extended survivorship. METHODS: In this retrospective cohort study, we compared 21,690 survivors of DLBCL from the California Cancer Registry (CCR) to survivors of breast, prostate, head and neck, and melanoma cancers. We linked their CCR records to a statewide database documenting hospital, emergency room, and ambulatory surgery visits and investigated the incidence of autoimmune conditions, immune deficiencies, and infections 1-10 years after cancer diagnosis. RESULTS: We found elevated incidence rate ratios (IRRs) for many immune-related conditions in survivors of DLBCL compared with other cancer survivors, including significantly and consistently elevated IRRs for viral and fungal pneumonias (up to 10.8-fold), meningitis (up to 5.3-fold), as well as humoral deficiency (up to 17.6-fold) and autoimmune cytopenias (up to 12-fold). IRRs for most conditions remained high even in the late survivorship period (5-10 years after cancer diagnosis). The elevated risks could not be explained by exposure to chemotherapy, stem-cell transplantation, or rituximab, except for IRRs for humoral deficiency, which were consistently higher after the incorporation of rituximab into DLBCL treatments. CONCLUSION: To our knowledge, this is the largest cohort study with extended follow-up to demonstrate impaired immune health in survivors of DLBCL. The observed persistent, elevated risks for autoimmune diseases, immune deficiencies, and infectious conditions may reflect persistent immune dysregulation caused by lymphoma or treatment and may lead to excess morbidity and mortality during survivorship. Improved understanding of these risks could meaningfully improve long-term care of patients with DLBCL.